Personalised Medicine and Patient Safety

Symposium programme

The era of personalised medicine represents a paradigm shift in healthcare: by tailoring diagnostics and therapies to each patient’s unique genetic profile, lifestyle and environment, clinicians can achieve far better outcomes than with one-size-fits-all approaches. In practice, this means more accurate diagnoses and more effective, individualized treatments – and crucially, a
substantial reduction in harmful side effects. For example, by understanding a patient’s genetic makeup, providers can predict and avoid adverse drug reactions, directly enhancing patient safety. Personalised medicine thus holds great promise for safer, more effective patient care, making it a pivotal focus of current research.

08:30

Registration

08:50 - 09:00

Opening of the symposium 

09:00 - 09:45

Implementation of PGx in clinical care: the DNA-passport for medication
Ron van Schaik, Professor, PhD, Department of Clinical Chemistry, Erasmus MC, Rotterdam

09:45 - 10:30

PGx and drug transporters
Mikko Niemi, Professor, MD, PhD, Dept. of Clinical Pharmacology, University of Helsinki

10:30 - 11:00

Coffee break and networking

11:00 - 11:30

Renal biomarkers
Morten Baltzer Houlind PhD, PostDoc, Department of Clinical Research, Hvidovre Hospital and Dept. of Drug Design and Pharmacology, University of Copenhagen

11:30 - 12:00

Can PGx testing contribute to prevention of medication-related admissions to the emergency department
Louise W.S Christensen, MSc. PhD student, Department of Clinical Research, Hvidovre Hospital and Dept. Depart of Drug Design and Pharmacology, University of Copenhagen

12:00 - 12:30

PGx in Psychiatry
Marlene Bentestuen, MD, PhD student, Dept. of Clinical Medicine, Aarhus University

12:30 - 13:15

Lunch and networking

13:15 - 14:00

Who are we really treating? Host genome profiling – and treatment effects
Kjeld Schmiegelow, Professor, MD, DMSc, Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet

14:00 - 14:30

Personalised treatment with Imatinib in patients with leukemia
Anna Buhl Rasmussen, MD, PhD student, Department of Clinical Pharmacology Bispebjerg and Frederiksberg University Hospital

14:30 - 15:00

Coffee break and networking

15:00 - 15:30

Imaging biomarkers of Vascular Dysfunction – Can we optimize Diagnosis and target treatment of peripheral neuropathy?
Trine Andresen, Associate Professor, MSc(pharm), PhD, Department of Health Science and Technology, Translational Pain Neuroscience and Precision Health, Center for Neuroplasticity and Pain, Aalborg University

15:30 - 16:15

TBA

16:15 - 16:30

Closing remarks

16:30 - 17:30

Farewell networking between senior researchers/clinicians and PhD students fuelled by snacks & drinks


The symposium is organized on behalf of the graduate programme in pharmaceutical sciences, Drug Research Academy, and the Danish Society for Personalised Medicine by Morten Baltzer Houlind, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen.

The symposium is free of charge and open for attendance by all interested parties. In order to avoid food waste it is necessary to register by 11 November to: llc@sund.ku.dk